- Home
- CASI vs MBRX Comparison
CASI vs MBRX Comparison
Compare CASI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- MBRX
- Stock Information
- Founded
- CASI 1991
- MBRX 2015
- Country
- CASI China
- MBRX United States
- Employees
- CASI N/A
- MBRX N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- MBRX Health Care
- Exchange
- CASI Nasdaq
- MBRX Nasdaq
- Market Cap
- CASI 24.9M
- MBRX 23.5M
- IPO Year
- CASI 1996
- MBRX 2016
- Fundamental
- Price
- CASI $1.30
- MBRX $0.44
- Analyst Decision
- CASI Strong Buy
- MBRX Strong Buy
- Analyst Count
- CASI 1
- MBRX 4
- Target Price
- CASI $4.00
- MBRX $5.00
- AVG Volume (30 Days)
- CASI 26.7K
- MBRX 5.2M
- Earning Date
- CASI 11-14-2025
- MBRX 11-12-2025
- Dividend Yield
- CASI N/A
- MBRX N/A
- EPS Growth
- CASI N/A
- MBRX N/A
- EPS
- CASI N/A
- MBRX N/A
- Revenue
- CASI $31,564,000.00
- MBRX N/A
- Revenue This Year
- CASI N/A
- MBRX N/A
- Revenue Next Year
- CASI N/A
- MBRX N/A
- P/E Ratio
- CASI N/A
- MBRX N/A
- Revenue Growth
- CASI 36.64
- MBRX N/A
- 52 Week Low
- CASI $1.09
- MBRX $0.25
- 52 Week High
- CASI $5.95
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- CASI 35.39
- MBRX 42.06
- Support Level
- CASI $1.29
- MBRX $0.46
- Resistance Level
- CASI $1.48
- MBRX $0.51
- Average True Range (ATR)
- CASI 0.13
- MBRX 0.05
- MACD
- CASI -0.00
- MBRX -0.00
- Stochastic Oscillator
- CASI 0.00
- MBRX 4.81
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.